Effects of palliative treatment with temozolomide in patients with high-grade gliomas

Neurologia i Neurochirurgia Polska

Volumn 42, Issue 3, 2008, Pages 210-215

  Ziobro, Marek ^a   Rolski, Janusz ^a   Grela Wojewoda, Aleksandra ^a   Zygulska, Aneta ^b   Niemiec, Maciej ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Krakowski Szpital Specjalistyczny im Jana Pawło II ^*  (Poland)

Author keywords

High grade gliomas; Palliative chemotherapy; Temozolomide

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; GLIOMA; GRANULOCYTOPENIA; HAIR LOSS; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIXED TUMOR; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POLAND; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; PALLIATIVE CARE; POLAND; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 48449083832     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Wojciechowska U., Dzidkowska J., Tarkowski W., et al. Nowotwory złośliwe w Polsce w 2002 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie, Warszawa 2004.
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Stupp R., Ostermann S., Leyvraz S., et al. Cerebrospinal fluid levels of temozolomide as surrogate marker for brain penetration. Proc Am Soc Clin Oncol 2001; 20: 59a (abstract 232).
4. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
5. Macdonald D.R., Cascino T.L., Schold Jr S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
6. Stewart L.A. Chemotherapy in adult high grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
7. Wilson C.B., Gutin P., Boldrey E.B., et al. Single-agent chemotherapy of brain tumors. A five year review. Arch Neurol 1976; 33: 739-744.
8. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
9. Brandes A.A., Nicolardi L., Tosoni A., et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 2006; 8: 253-260.
10. Brandes A.A., Tosoni A., Cavallo G., et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006; 95: 1155-1160.
11. Chinot O.L., Barrié M., Fuentes S., et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007; 25: 1470-1475.
12. Khan R.B., Raizer J.J., Malkin M.G., et al. A phase II study of extended low-dose temozolomide in recurrent maligant gliomas. Neuro Oncol 2002; 4: 39-43.
13. Brada M., Hoang-Xuan K., Rampling R., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12: 259-266.
14. Brandes A.A., Ermani M., Basso U., et al. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea - procarbazine failure: a phase II study. Oncology 2002; 63: 38-41.
15. O'Reilly S.M., Newlands E.S., Glaser M.G., et al. Temozolomide: a new oral chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993; 29A: 940-942.
16. Yung W.K., Prados M.D., Yaya-Tur R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17: 2762-2771.
17. Trent S., Kong A., Short S.C., et al. Temozolomide as second-line chemotherapy for relapsed gliomas. J Neurooncol 2002; 57: 247-251.
18. Bower M., Newlands E.S., Bleehen N.M., et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997; 40: 484-488.